Oncology-inspired treatment options for COVID-19 Journal Article
| Authors: | Pillarsetty, N.; Carter, L. M.; Lewis, J. S.; Reiner, T. |
| Article Title: | Oncology-inspired treatment options for COVID-19 |
| Abstract: | CR3022 is a human antibody that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we explore the use of CR3022 as a molecularly targeted radiotherapeutic. Methods: CR3022 was labeled with 131I and purified, yielding 131I-CR3022. Using a magnetic bead assay and a recombinant SARS-CoV-2 spike protein fragment, we tested binding of 131I-CR3022 in the presence and absence of CR3022. Results: We conjugated the antibody CR3022 with a purity of more than 98% and a specific activity of more than 292 MBq/mg. Using a bead-based assay, we confirmed that binding of 131I-CR3022 is selective and is significantly reduced in the presence of unlabeled antibody (3.14% ± 0.14% specific uptake and 0.10% ± 0.01% specific uptake, respectively; P < 0.0001). Conclusion: Our results confirm the potential of CR3022 as a molecularly targeted probe for SARS-CoV-2. A labeled version of CR3022 could potentially be used for Auger radiotherapy or noninvasive imaging. © 2020 by the Society of Nuclear Medicine and Molecular Imaging. |
| Keywords: | radiotherapy; covid-19; sars-cov-2; auger; cr3022 |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 61 |
| Issue: | 12 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2020-12-01 |
| Start Page: | 1720 |
| End Page: | 1723 |
| Language: | English |
| DOI: | 10.2967/jnumed.120.249748 |
| PUBMED: | 32680924 |
| PROVIDER: | scopus |
| PMCID: | PMC8679628 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 4 January 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
132Pillarsetty -
456Lewis -
136Reiner -
79Carter
Related MSK Work